Quel est le prix pour Ocean Biomedical, Inc. (OCEAW)

Le prix pour Ocean Biomedical, Inc. (OCEAW) est $0.0298

Quelle est la capitalisation boursière pour Ocean Biomedical, Inc. (OCEAW)

La capitalisation boursière pour Ocean Biomedical, Inc. (OCEAW) est $7.94M

Ocean Biomedical, Inc. (OCEAW) Ratio P/B

Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in identifying and advancing novel therapeutic agents. Their research and development efforts span several key disease areas, including cancer, fibrotic conditions, infectious illnesses, and inflammatory disorders. The company's current development pipeline features both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are engineered to target Chi3l1 and are being investigated for treating non-small cell lung cancer and glioblastoma multiforme, a type of brain tumor. Furthermore, Ocean Biomedical is progressing a small molecule therapeutic designed to interact with Chit1, intended for individuals afflicted with Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Their proprietary WPDS platform has generated three additional product candidates: a vaccine aimed at preventing malaria; a humanized monoclonal antibody treatment; and a small molecule treatment, with both malaria therapeutics specifically targeting the Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company is also developing a therapy for hospitalized patients suffering from COVID-19. Founded in 2019, Ocean Biomedical's operations are headquartered in Providence, Rhode Island.

Année	Ratio P/B	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/B

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/B	Différence de Ratio P/B	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	-	BE

Entreprise

Ratio P/B

Différence de Ratio P/B

Pays